Privacy Policy
Signals Blog

Contributors

Categories

Update from the Clinic: July

. Welcome to your update from the Clinic for the month of July. Adaptimmune moves a second candidate into the clinic. Ziopharm receives an Orphan Drug Designation for its cutting edge IL-12 technology. Canadian cell therapy company, Hemostemix, keeps moving forward...

Right Turn: This is not a One Direction concert review

. Last night, I took my daughters to a One Direction concert. Regardless of what you might now think of me (us), they still have several (million) fans around the world. The 40,000 screaming girls in attendance at the Rogers Centre showed the Brit boys lots of love....

Cell Therapy Deal Review: July

. Welcome to your Cell Therapy Deal Review for the month of July. Here at Signals we’ve decided to change the name of this monthly column, to pay consideration to the fact the majority of the technologies discussed here are cell-based. Moving forward, I will continue...

Right Turn: George Daley on The Stem Cell Podcast

. Do you listen to The Stem Cell Podcast? If not, why not? Last September, former Signals co-editor Lisa Willemse blogged about the podcast, which, at the time, was celebrating its first anniversary. The hosts and creators behind the podcast are celebrating another...

Right Turn: #ILookLikeAnEngineer

. First female scientists were #DistractinglySexy – and hilarious, I might add. (If this means nothing to you, I recommend you read this article for a good recap.) Now their female engineering friends and colleagues are also tackling sexism in STEM – science,...

Right Turn: Putting your money where your mouth is

. Tomorrow (or today for you readers), I’m heading to a BBQ. Canadians love to BBQ. I don’t have any stats on this, but I was born in Canada and I know this to be true. To further support my statement, Google says Canada “leads the world when it comes to online...

Regenerative Medicine Deal Review: June

. Welcome to your Regenerative Medicine Deal Review for the month of June. It was an epic month in partnerships that saw multiple collaborations closely tying industry leaders together. Almost all public cell-based immunotherapy companies have formed partnerships with...

Right Turn: Greg Bonfiglio on investing in RM

. You are probably ready for something more substantial from Right Turn after three weeks of light vacations posts. I have something that fits the bill. Greg Bonfiglio, Founder and Managing Partner of Proteus Venture Partners, was interviewed by PharmaTelevision in...

Subscribe to Signals

Subscribe to our blog list to receive the latest news and updates.

You have Successfully Subscribed!